Revenue and Profitability - The company's total revenue for the reporting period (January 1, 2022, to June 30, 2022) was CNY 92.21 million, with overseas sales accounting for 87.21% of total revenue, amounting to CNY 80.42 million[14]. - The company's operating revenue for the current period is ¥92,205,975.82, a decrease of 7.54% compared to the previous year[27]. - The net profit attributable to shareholders increased by 86.20% to ¥20,539,424.47, compared to ¥11,030,554.78 in the same period last year[27]. - The gross profit margin improved to 45.26%, up from 36.47% in the previous year[27]. - The revenue from hearing aids was ¥87,271,582.13, with a gross margin of 45.99%, reflecting a year-on-year increase of 8.73%[52]. - The company achieved operating revenue of 92.21 million yuan, a year-on-year decrease of 7.54%, while net profit attributable to shareholders increased by 86.20% to 20.54 million yuan[36]. Assets and Liabilities - The company’s total assets increased by 2.10% to ¥383,518,724.26, while total liabilities decreased by 5.87% to ¥40,121,757.63[28]. - As of June 30, 2022, total assets amounted to 383.52 million yuan, with net assets attributable to shareholders at 344.69 million yuan, reflecting growth of 2.10% and 3.26% respectively compared to the beginning of the period[36]. - The total assets increased from ¥375,622,625.19 to ¥383,518,724.26, a growth of about 2.4%[151]. - Current liabilities decreased from ¥40,438,314.48 to ¥30,581,390.58, a reduction of approximately 24%[151]. Cash Flow - The net cash flow from operating activities was ¥7,468,514.74, a significant recovery from a negative cash flow of ¥17,817,167.16 in the previous year[29]. - The net cash flow from operating activities for the first half of 2022 was ¥7,468,514.74, a significant improvement compared to a net outflow of ¥17,817,167.16 in the same period of 2021[165]. - Cash inflow from investment activities surged to ¥281,981,430.61, a substantial increase from ¥30,524,052.06 in the first half of 2021[166]. - The total cash and cash equivalents at the end of the period stood at ¥67,658,365.54, down from ¥71,640,283.15 at the beginning of the period[166]. Research and Development - The company invested ¥6,651,300 in R&D, an increase of 22.59% year-on-year, and obtained 10 new patent authorizations during the reporting period[35]. - Research and development expenses increased to CNY 6,651,300.70 in the first half of 2022, compared to CNY 5,425,756.80 in the same period of 2021, reflecting a growth of 22.6%[159]. - The company has reported significant research and development expenditures, reflecting its commitment to innovation and future growth[182]. Market Presence and Expansion - The company is actively expanding its market presence through participation in various domestic and international exhibitions to acquire new customers and orders[14]. - The company has established two specialized stores in the domestic market to enhance brand promotion and market presence[35]. - The company plans to enhance brand recognition and domestic sales through e-commerce platforms and self-operated stores[71]. - The company is increasing its investment in domestic operations and aims to balance its domestic and overseas sales, reducing reliance on foreign markets[71]. Corporate Governance and Compliance - The company has established a modern corporate governance structure, but there are risks associated with the actual controllers' influence over major decisions[13]. - The company is currently fulfilling its commitment to avoid any illegal occupation of funds and assets, as well as external guarantees[83]. - The company has committed to strictly adhere to regulations regarding the lock-up and reduction of shares, which is currently being fulfilled[84]. - The company is actively working on reducing related party transactions and is in compliance with this commitment[83]. Shareholder and Equity Information - The company distributed a cash dividend of CNY 2.00 per 10 shares on June 1, 2022[131]. - The total number of unrestricted shares increased from 14,792,635 to 16,966,635, representing a rise from 30.44% to 34.43% of total shares[113]. - The total share capital increased from 48,600,000 to 49,275,000 shares due to the implementation of the 2022 equity incentive plan, which involved the issuance of 675,000 restricted shares[115]. - The company has a three-year dividend return plan for shareholders following the public issuance of shares[85]. Risks and Challenges - The company faces risks related to foreign exchange fluctuations, as its products are primarily priced in USD, impacting revenue when converted to CNY[14]. - The company is facing risks from geopolitical conflicts and trade tensions that may affect its overseas sales and overall performance[71]. - The company has implemented foreign exchange hedging tools to mitigate the impact of currency fluctuations on its performance[72]. Other Financial Information - The company reported a financial expense of CNY -1,441,503.31 in the first half of 2022, compared to CNY 821,561.29 in the same period of 2021, indicating a positive shift in financial management[159]. - The company recognized 54 core employees, with the latest count at 53 after one resignation[145]. - The company has not made any changes to accounting policies or estimates compared to the previous year, ensuring consistency in financial reporting[182].

Financial Performance - Net profit attributable to shareholders for the first quarter of 2022 was CNY 5,586,935.69, a decrease of 10.83% compared to CNY 6,265,365.91 in the same period last year[15] - Operating revenue for the first quarter of 2022 was CNY 37,694,584.15, down 1.42% from CNY 38,237,391.48 year-on-year[15] - Basic earnings per share decreased by 32.38% to CNY 0.11 from CNY 0.17 in the same period last year[15] - The company's net cash flow from operating activities for the first quarter was CNY 7,272,807.75, a decline of 3.42% compared to CNY 7,530,507.15 in the previous year[15] - Comprehensive income for Q1 2022 totaled 5,365,879.18, compared to 6,080,797.96 in Q1 2021, reflecting a decrease of about 11.8%[50] - Operating profit for Q1 2022 was 5,706,635.43, compared to 6,807,626.86 in Q1 2021, showing a decline of around 16.2%[46] - Total operating revenue for Q1 2022 was 37,674,137.74, a decrease from 38,237,391.48 in Q1 2021, representing a decline of approximately 1.5%[48] - Net profit for Q1 2022 was 5,365,879.18, down from 6,080,797.96 in Q1 2021, indicating a decrease of about 11.8%[46] Assets and Liabilities - Total assets as of March 31, 2022, amounted to CNY 379,752,076.69, reflecting a 1.10% increase from CNY 375,622,625.19 at the end of the previous year[15] - The company's total liabilities to assets ratio was 10.90% as of March 31, 2022, down from 11.35% at the end of the previous year[15] - The net assets attributable to shareholders increased to CNY 339,377,445.23, representing a 1.67% increase from CNY 333,790,509.54 at the end of the previous year[15] - Current liabilities decreased to CNY 39,239,452.20 from CNY 40,438,314.48, a reduction of approximately 2.96%[38] - Total liabilities decreased to CNY 41,389,558.88 from CNY 42,625,986.56, indicating a decline of about 2.91%[39] - Shareholders' equity increased to CNY 338,362,517.81 from CNY 332,996,638.63, showing a growth of approximately 1.10%[39] Cash Flow - Cash and cash equivalents decreased from ¥71,640,283.15 on December 31, 2021, to ¥41,570,848.36 on March 31, 2022, representing a decline of approximately 42%[37] - Operating cash inflow for Q1 2022 was CNY 46,223,409.90, a decrease of 21.0% from CNY 58,626,742.69 in Q1 2021[51] - Cash inflow from operating activities for the parent company in Q1 2022 was CNY 46,170,386.26, down from CNY 58,627,113.60 in Q1 2021[54] - The parent company's net cash flow from operating activities in Q1 2022 was CNY 6,765,897.00, a decrease from CNY 8,011,473.90 in Q1 2021[54] - Cash outflow for purchasing goods and services in Q1 2022 was CNY 24,862,533.50, down 30.2% from CNY 35,537,659.34 in Q1 2021[51] Shareholder Information - The number of ordinary shareholders as of the report date was 8,513[21] - The major shareholders include Wang Min with 26.07% and Wang Fang with 19.53% of the total shares[24] - The total shares held by the top ten shareholders amount to 37,256,377, representing 76.67% of the total shares[24] Commitments and Compliance - The company has committed to avoiding related party transactions and ensuring compliance with regulations[29] - The company has confirmed that all previously disclosed commitments are being fulfilled[29] - The company committed to avoiding all illegal occupation of funds and guarantees by the company and its subsidiaries[30] - The company has also committed to publicly disclosing information and ensuring there are no false records or misleading statements as of October 30, 2020[33] Investments and Expenses - Research and development expenses increased to 3,042,481.56 in Q1 2022 from 2,376,842.25 in Q1 2021, reflecting a growth of approximately 27.9%[46] - Long-term equity investments rose to CNY 9,637,742.33 from CNY 5,600,000.00, an increase of approximately 72.80%[42] - Investment income for Q1 2022 was 158,080.00, down from 485,846.58 in Q1 2021, indicating a decline of about 67.5%[46] Other Financial Metrics - The total non-recurring gains and losses for the first quarter amounted to CNY 378,919.17 after tax[19] - Financial expenses decreased to 392,582.84 in Q1 2022 from 492,377.92 in Q1 2021, a reduction of approximately 20.2%[46] - The company reported a credit impairment loss of 122,066.95 in Q1 2022, significantly lower than 637,683.86 in Q1 2021, a decrease of approximately 80.9%[46]

Financial Performance - The total operating revenue for the reporting period was CNY 191.95 million, with overseas revenue accounting for CNY 165.45 million, representing 86.19% of total sales[17]. - The company's operating revenue for 2021 was ¥191,946,299.04, a decrease of 9.24% compared to ¥211,480,597.53 in 2020[29]. - The net profit attributable to shareholders for 2021 was ¥22,881,399.64, down 44.72% from ¥41,388,470.16 in 2020[29]. - The company's net profit growth rate for 2021 was -45.49%, compared to a growth rate of 65.08% in 2020[34]. - The company achieved operating revenue of CNY 191.95 million, a decrease of 9.24% year-on-year[49]. - The net profit attributable to shareholders was CNY 22.88 million, a decrease of 44.72% year-on-year, impacted by exchange rate fluctuations and rising raw material costs[49]. - The gross profit margin decreased to 37.59% from 41.85% in the previous year, indicating pressure on profitability[60]. - The company's total revenue for the reporting period was 191,946,299.04 yuan, a decrease of 9.24% compared to the same period last year[71]. - The revenue from nebulizers was 22,866,022.76 yuan, down 50.13% year-on-year, primarily due to rising raw material prices affecting profit margins[71]. - The cash flow from operating activities for 2021 was ¥25,225,648.78, a decrease of 43.37% from ¥44,544,867.68 in 2020[32]. Research and Development - The company invested CNY 12.14 million in R&D, an increase of 13.79% year-on-year, and CNY 24.76 million in sales expenses, an increase of 22.40% year-on-year[49]. - The company has focused on R&D projects such as DSP digital chips and self-developed hearing test algorithms, with the DSP digital chip now in mass production[98]. - The company plans to continue investing in R&D, focusing on AI algorithms for the next generation of hearing aids to maintain its competitive edge[98]. - Research and development (R&D) expenditure for the current period was ¥12,136,110.72, representing 6.32% of operating revenue, an increase from 5.04% in the previous period[94]. - The proportion of R&D personnel in the total workforce was 14.83% at the end of the period, slightly up from 14.24% at the beginning[95]. Market Expansion and Strategy - The company is actively expanding its market presence through participation in various domestic and international exhibitions[16]. - The company aims to expand its market presence in North America and Europe, leveraging the recovery post-COVID-19 and the launch of the OTC market[107]. - The company plans to develop digital hearing aids, focusing on OTC, intelligent, and personalized trends to better meet market demands[108]. - The company targets to increase its revenue from BTC business and promote its own brand in the domestic market[110]. - The company plans to reduce reliance on overseas markets by increasing domestic sales efforts and expanding sales channels[118]. Corporate Governance and Compliance - The company has established a modern corporate governance structure, which is crucial for its continued growth and compliance with regulatory requirements[15]. - The company is currently fulfilling its commitment to avoid any illegal occupation of funds, assets, and external guarantees[130]. - The company has committed to strictly adhere to regulations regarding the lock-up and reduction of shares, ensuring compliance with relevant requirements[130]. - The company has publicly disclosed that there are no false records or misleading statements in its information submissions[133]. - The company has committed to ensuring that the public offering documents do not contain false records, misleading statements, or significant omissions, and will repurchase all newly issued shares if such issues are identified[170]. Risks and Challenges - The company has faced challenges due to the global pandemic, impacting new order acquisition and overall sales performance[16]. - The company has identified several major risks, including potential changes in export tax policies and the impact of external market conditions on sales[15]. - The company faces uncertainties due to the ongoing global pandemic, rising raw material prices, and exchange rate fluctuations[113]. - The company faces risks from exchange rate fluctuations due to its high overseas sales, which may impact financial performance[119]. - The company has implemented measures such as foreign exchange hedging to mitigate exchange rate risks[119]. Shareholder Commitments and Stock Management - The company issued a total of 1,250,000 shares in 2021, increasing the total share capital to 48,600,000 shares[26]. - The company will repurchase shares to stabilize stock prices, with the repurchase amount not exceeding 20% of the previous year's audited net profit attributable to shareholders[142]. - The controlling shareholder will increase their holdings if the stock price stabilization measures are triggered, with a minimum investment of 20% of the previous year's cash dividends[140]. - The company has committed to a profit distribution policy that ensures cash dividends will not exceed 10% of the distributable profits for the year, with a cumulative cash distribution of at least 30% of the average annual distributable profits over the last three years[162]. - The company will prioritize cash dividends when conditions allow, ensuring a stable and continuous return to investors[161].